Cite
Imam F, Al-Harbi NO, Al-Harbi MM, et al. Corrigendum to "Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways" [Pharmacol. Rep. 70 (2018) 993-1000]. Pharmacol Rep. 2019;71(6):1227doi: 10.1016/j.pharep.2019.06.009.
Imam, F., Al-Harbi, N. O., Al-Harbi, M. M., Ansari, M. A., Al-Asmari, A. F., Ansari, M. N., Al-Anazi, W. A., Bahashwan, S., Almutairi, M. M., Alshammari, M., Khan, M. R., Alsaad, A. M., & Alotaibi, M. R. (2019). Corrigendum to "Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways" [Pharmacol. Rep. 70 (2018) 993-1000]. Pharmacological reports : PR, 71(6), 1227. https://doi.org/10.1016/j.pharep.2019.06.009
Imam, Faisal, et al. "Corrigendum to "Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways" [Pharmacol. Rep. 70 (2018) 993-1000]." Pharmacological reports : PR vol. 71,6 (2019): 1227. doi: https://doi.org/10.1016/j.pharep.2019.06.009
Imam F, Al-Harbi NO, Al-Harbi MM, Ansari MA, Al-Asmari AF, Ansari MN, Al-Anazi WA, Bahashwan S, Almutairi MM, Alshammari M, Khan MR, Alsaad AM, Alotaibi MR. Corrigendum to "Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways" [Pharmacol. Rep. 70 (2018) 993-1000]. Pharmacol Rep. 2019 Dec;71(6):1227. doi: 10.1016/j.pharep.2019.06.009. Epub 2019 Oct 25. PMID: 31669887.
Copy
Download .nbib